What is the appropriate starting dose and titration plan for escitalopram (Lexapro) in a 71‑year‑old patient, considering QT‑interval risk, cardiac risk factors, potential CYP2C19 interactions, and possible hepatic impairment?

Escitalopram Dosing in a 71-Year-Old Patient

Start with 10 mg once daily and do not exceed this dose in this patient, given the age >65 years, established QT-prolongation risk, and need for cardiac monitoring. 1

Starting Dose and Maximum Dose

The FDA label explicitly states that the recommended dosage for elderly patients is 10 mg daily 1. This reduced maximum dose (compared to 20 mg in younger adults) is based on pharmacokinetic data showing escitalopram half-life increases by approximately 50% in patients ≥65 years, leading to higher drug exposure 1.

Do not titrate above 10 mg daily in this patient. The standard adult titration to 20 mg is contraindicated in elderly patients due to:

• Increased cardiac arrest risk (OR 1.21 for SSRIs overall) 2
• Age-dependent reduction in drug clearance causing 20% of patients >65 years to reach potentially pro-arrhythmic concentrations even at 10 mg 3
• FDA/EMA dose restrictions specifically for patients >60 years due to QT-prolongation studies 2

Critical QT-Interval Monitoring

Obtain a baseline ECG before initiating escitalopram 4. Among SSRIs, escitalopram carries the highest QT-prolongation risk alongside citalopram, classified as having "conditional TdP risk" 4. The 2023 Canadian Cardiovascular Society guidelines specifically identify escitalopram as high-risk, with negligible risk alternatives being paroxetine and sertraline 4.

When to Obtain Follow-up ECGs:

• If baseline QTc >450 ms (men) or >460 ms (women)
• If patient has cardiac risk factors (structural heart disease, bradycardia, electrolyte abnormalities)
• If adding any other QT-prolonging medication
• If QTc increases >60-70 ms from baseline or exceeds 500 ms at any point 4

Critical threshold: Keep serum concentrations below 100 nM to reduce arrhythmia risk 3. Recent 2023 data demonstrates therapeutic concentrations of escitalopram show pro-arrhythmic changes in human cardiac action potentials, with risk increasing substantially in patients >65 years 3.

Hepatic Impairment Considerations

If hepatic impairment is present or suspected, the maximum dose is 10 mg daily 1. No further dose adjustment is needed, but this reinforces that 10 mg is the ceiling dose for this patient regardless of response.

CYP2C19 Metabolizer Status

While the FDA label doesn't require genotyping, CYP2C19 poor metabolizers (PMs) have significantly reduced clearance and face higher toxicity risk 5, 6, 7:

• Extensive/Intermediate Metabolizers: Standard 10 mg dosing appropriate
• Poor Metabolizers: Consider starting at 5 mg daily if genotype known, as PMs show markedly elevated drug exposure 6
• Age amplifies CYP2C19 effects: older PMs have 2-3 fold higher risk of adverse events 6, 7

Phenoconversion risk: Even intermediate metabolizers can behave as poor metabolizers when combined with CYP2C19 inhibitors (omeprazole, esomeprazole, fluconazole, fluoxetine) 8, 7. Avoid these combinations or reduce escitalopram to 5 mg if unavoidable.

Mandatory Monitoring

Electrolytes (Critical):

• Check potassium, magnesium, and sodium before starting and regularly during treatment 4
• Hypokalemia dramatically increases SQTP risk in a dose-dependent manner 9
• SSRIs cause clinically significant hyponatremia in elderly patients 1—monitor sodium every 2-4 weeks initially

Renal Function:

• No dose adjustment needed for mild-moderate renal impairment 1
• Severe renal impairment (CrCl <20 mL/min) not studied—use with extreme caution

Practical Dosing Algorithm

1. Obtain baseline ECG and comprehensive metabolic panel
2. Start 10 mg once daily (morning or evening, with/without food) 1
3. Reassess at 4 weeks: If inadequate response, DO NOT increase dose
4. If inadequate response at 10 mg: Switch to alternative antidepressant (consider sertraline or paroxetine—negligible QT risk) 4 rather than increasing escitalopram dose
5. Monitor electrolytes every 2-4 weeks for first 3 months, then quarterly
6. Repeat ECG if: Adding medications, symptoms of arrhythmia, or electrolyte disturbances

Critical Drug Interactions to Avoid

Absolute contraindications (do not co-prescribe):

• Other QT-prolonging drugs (methadone, antipsychotics, macrolides, fluoroquinolones) 4
• Strong CYP2C19 inhibitors unless dose reduced to 5 mg 7

Safer alternatives when needed:

• Antibiotics: Use penicillins or cephalosporins instead of macrolides/fluoroquinolones 4
• Antiemetics: Use aprepitant or dexamethasone instead of ondansetron 4

Discontinuation

Taper gradually when stopping 1. Reduce to 5 mg daily for 1-2 weeks before complete discontinuation to minimize withdrawal symptoms.

Key Pitfalls to Avoid

1. Never exceed 10 mg daily in patients >65 years—this is an FDA-mandated maximum, not a target 1
2. Do not assume "therapeutic dose" equals "safe dose"—severe toxicity occurs at standard doses in elderly patients 3, 8
3. Do not rely solely on drug levels—cardiac toxicity can occur at non-toxic serum concentrations due to pharmacodynamic factors 8
4. Do not skip baseline ECG—escitalopram is high-risk for QT prolongation 4
5. Monitor sodium aggressively—elderly patients are at highest risk for SIADH 1, 8